A citation-based method for searching scientific literature

Lakshmi Nayak, Fabio M Iwamoto, Jeremy D Rudnick, Andrew D Norden, Eudocia Quant Lee, Jan Drappatz, Antonio Omuro, Thomas J Kaley. J Neurooncol 2012
Times Cited: 110







List of co-cited articles
784 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Emil Lou, Ashley L Sumrall, Scott Turner, Katherine B Peters, Annick Desjardins, James J Vredenburgh, Roger E McLendon, James E Herndon, Frances McSherry, Julie Norfleet,[...]. J Neurooncol 2012
114
69

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
143
57

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
486
34

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Thomas Kaley, Igor Barani, Marc Chamberlain, Michael McDermott, Katherine Panageas, Jeffrey Raizer, Leland Rogers, David Schiff, Michael Vogelbaum, Damien Weber,[...]. Neuro Oncol 2014
125
34

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Andrew D Norden, Jeffrey J Raizer, Lauren E Abrey, Kathleen R Lamborn, Andrew B Lassman, Susan M Chang, W K Alfred Yung, Mark R Gilbert, Howard A Fine, Minesh Mehta,[...]. J Neurooncol 2010
108
32

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.
Jeffrey J Raizer, Sean A Grimm, Alfred Rademaker, James P Chandler, Kenji Muro, Irene Helenowski, Laurie Rice, Katie McCarthy, Sandra K Johnston, Maciej M Mrugala,[...]. J Neurooncol 2014
61
52

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth. J Neurooncol 2016
50
60

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, Andrew D Norden, Timothy F Cloughesy, Lauren E Abrey, Howard A Fine, Susan M Chang, H Ian Robins, Karen Fink,[...]. Neuro Oncol 2009
90
32

Bevacizumab-induced regression of anaplastic meningioma.
M J A Puchner, V H Hans, A Harati, F Lohmann, M Glas, U Herrlinger. Ann Oncol 2010
52
55


Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
377
28

Temozolomide for treatment-resistant recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. Neurology 2004
101
28

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
Marc C Chamberlain, Michael J Glantz, Camilo E Fadul. Neurology 2007
120
28

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
David A Reardon, Andrew D Norden, Annick Desjardins, James J Vredenburgh, James E Herndon, April Coan, John H Sampson, Sridharan Gururangan, Katherine B Peters, Roger E McLendon,[...]. J Neurooncol 2012
49
51

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
25


Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.
Yongli Ji, Cathryn Rankin, Steven Grunberg, Andy E Sherrod, Jamshid Ahmadi, Jeannette J Townsend, Lynn G Feun, Ruth K Fredericks, Christy A Russell, Fairooz F Kabbinavar,[...]. J Clin Oncol 2015
65
36

Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
Fabio P Nunes, Vanessa L Merker, Dominique Jennings, Paul A Caruso, Emmanuelle di Tomaso, Alona Muzikansky, Fred G Barker, Anat Stemmer-Rachamimov, Scott R Plotkin. PLoS One 2013
61
37

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Marta Simó, Andreas A Argyriou, Miquel Macià, Gerard Plans, Carles Majós, Noemi Vidal, Miguel Gil, Jordi Bruna. Cancer Chemother Pharmacol 2014
40
55


Salvage chemotherapy with CPT-11 for recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. J Neurooncol 2006
64
31

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
20

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Andrew D Norden, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, Scott R Plotkin, Jeffrey J Raizer, Eric T Wong,[...]. Neurology 2015
51
39

EANO guidelines for the diagnosis and treatment of meningiomas.
Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen,[...]. Lancet Oncol 2016
377
20


Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
Derek R Johnson, David W Kimmel, Patrick A Burch, Terrence L Cascino, Caterina Giannini, Wenting Wu, Jan C Buckner. Neuro Oncol 2011
52
36

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
Steven M Grunberg, Martin H Weiss, Christy A Russell, Irving M Spitz, Jamshid Ahmadi, Alfredo Sadun, Regine Sitruk-Ware. Cancer Invest 2006
107
19

Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab.
S Goutagny, E Raymond, O Sterkers, J M Colombani, M Kalamarides. Ann Oncol 2011
39
48

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
330
19

Medical therapies for meningiomas.
Patrick Y Wen, Eudocia Quant, Jan Drappatz, Rameen Beroukhim, Andrew D Norden. J Neurooncol 2010
101
18

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
304
18

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
Julia Furtner, Veronika Schöpf, Katharina Seystahl, Emilie Le Rhun, Roberta Rudà, Ulrich Roelcke, Susanne Koeppen, Anna Sophie Berghoff, Christine Marosi, Paul Clement,[...]. Neuro Oncol 2016
36
50

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
U M Schrell, M G Rittig, M Anders, U H Koch, R Marschalek, F Kiesewetter, R Fahlbusch. J Neurosurg 1997
132
17

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.
J W Goodwin, J Crowley, H J Eyre, B Stafford, K A Jaeckle, J J Townsend. J Neurooncol 1993
98
17

Pathological classification and molecular genetics of meningiomas.
Christian Mawrin, Arie Perry. J Neurooncol 2010
266
17

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Malak Abedalthagafi, Wenya Linda Bi, Ayal A Aizer, Parker H Merrill, Ryan Brewster, Pankaj K Agarwalla, Marc L Listewnik, Dora Dias-Santagata, Aaron R Thorner, Paul Van Hummelen,[...]. Neuro Oncol 2016
148
17

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
188
17

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Hadrien Peyrière, Noémie Basset, Didier Autran, Catherine Roche, Michel Kalamarides,[...]. Clin Cancer Res 2020
39
43

The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.
S E Kaba, F DeMonte, J M Bruner, A P Kyritsis, K A Jaeckle, V Levin, W K Yung. Neurosurgery 1997
95
16

Trabectedin has promising antineoplastic activity in high-grade meningioma.
Matthias Preusser, Sabine Spiegl-Kreinecker, Daniela Lötsch, Adelheid Wöhrer, Maria Schmook, Karin Dieckmann, Walter Saringer, Christine Marosi, Walter Berger. Cancer 2012
43
37


Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Warren P Mason, Fred Gentili, David R Macdonald, Subramanian Hariharan, Charlene R Cruz, Lauren E Abrey. J Neurosurg 2002
104
15

Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.
S M Grunberg, M H Weiss, I M Spitz, J Ahmadi, A Sadun, C A Russell, L Lucci, L L Stevenson. J Neurosurg 1991
275
15

Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches.
Matthias Preusser, Marco Hassler, Peter Birner, Margaretha Rudas, Till Acker, Karl H Plate, Georg Widhalm, Engelbert Knosp, Helene Breitschopf, Johannes Berger,[...]. Clin Neuropathol 2012
40
37


mTORC1 inhibitors suppress meningioma growth in mouse models.
Doreen Pachow, Nadine Andrae, Nadine Kliese, Frank Angenstein, Oliver Stork, Annette Wilisch-Neumann, Elmar Kirches, Christian Mawrin. Clin Cancer Res 2013
68
20

Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas.
Michael E Sughrue, Nader Sanai, Gopal Shangari, Andrew T Parsa, Mitchel S Berger, Michael W McDermott. J Neurosurg 2010
93
13

WHO grade II and III meningiomas: a study of prognostic factors.
Anne Durand, François Labrousse, Anne Jouvet, Luc Bauchet, Michel Kalamaridès, Philippe Menei, Robert Deruty, Jean Jacques Moreau, Michelle Fèvre-Montange, Jacques Guyotat. J Neurooncol 2009
202
13

Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas.
Peter Baumgarten, Benjamin Brokinkel, Jenny Zinke, Cornelia Zachskorn, Heinrich Ebel, Friedrich K Albert, Walter Stummer, Karl H Plate, Patrick N Harter, Martin Hasselblatt,[...]. Histol Histopathol 2013
23
56

The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
Winward Choy, Won Kim, Daniel Nagasawa, Stephanie Stramotas, Andrew Yew, Quinton Gopen, Andrew T Parsa, Isaac Yang. Neurosurg Focus 2011
120
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.